Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries by De Luca, Leonardo et al.








Comparison of P2Y12 receptor inhibitors in patients with ST-elevation
myocardial infarction in clinical practice: a propensity score analysis of five
contemporary European registries
De Luca, Leonardo ; Zeymer, Uwe ; Claeys, Marc J ; Dörler, Jakob ; Erne, Paul ; Matter, Christian M ;
Radovanovic, Dragana ; Weidinger, Franz ; Lüscher, Thomas F ; Jukema, J Wouter
Abstract: INTRODUCTION Among acute coronary syndromes (ACS), ST-segment elevation myocar-
dial infarction (STEMI) has the most severe early clinical course. Recent randomized clinical trials have
demonstrated that novel antithrombotic therapies improve in-hospital outcomes in STEMI patients. We
aimed to describe the effectiveness and safety of P2Y12 receptor inhibitors in clinical practice in patients
with STEMI based on data from contemporary European ACS registries. METHODS AND RESULTS
Five registries from the PIRAEUS initiative (AAPCI/ADPAT, ALKK-PIC, AMIS Plus, Belgium STEMI,
EYESHOT) provided data for the assessment of P2Y12 receptor inhibitor-based dual antiplatelet ther-
apy. Registries were heterogeneous in terms of setting, patient characteristics and treatment selection.
Matched pair analysis and propensity score matching were used to assess all-cause in-hospital death rates
based on data from 25’250 patients (8’577 patients on prasugrel, 5’995 on ticagrelor, and 10’678 on clopi-
dogrel). The odds ratio for death of any cause when compared to clopidogrel were 0.72 (CI 0.62 - 0.84,
p < 0.001) in favor of the new P2Y12 receptor inhibitors (prasugrel and ticagrelor combined). In the
comparison between prasugrel and ticagrelor, there were no relevant differences (OR 0.97; CI 0.77 -1.23,
p = 0.81). Event rates of cardiovascular death and stroke were also substantially lower for the new P2Y12
receptor inhibitors. The differences between clopidogrel and prasugrel or ticagrelor on major bleeding
were numerically in the same order as for death of any cause, but were not statistically significant. No
differences in ischemic and bleeding outcomes were observed between prasugrel and ticagrelor. CON-
CLUSION This analysis suggests that the prasugrel or ticagrelor compared to clopidogrel have favorable
outcomes in clinical practice while not being inferior in terms of safety.
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Aims Among acute coronary syndromes (ACS), ST-segment elevation myocardial infarction (STEMI) has the most severe
early clinical course. Recent randomized clinical trials have demonstrated that novel antithrombotic therapies im-
prove in-hospital outcomes in STEMI patients. We aimed to describe the effectiveness and safety of P2Y12 receptor




Five registries from the PIRAEUS initiative (AAPCI/ADPAT, ALKK-PIC, AMIS Plus, Belgium STEMI, and EYESHOT)
provided data for the assessment of P2Y12 receptor inhibitor-based dual antiplatelet therapy. Registries were het-
erogeneous in terms of setting, patient characteristics, and treatment selection. Matched pair analysis and propen-
sity score matching were used to assess all-cause in-hospital death rates based on data from 25 250 patients (8577
patients on prasugrel, 5995 on ticagrelor, and 10 678 on clopidogrel). The odds ratio (OR) for the death of any
cause when compared with clopidogrel was 0.72 [95% confidence interval (CI) 0.62–0.84, P<0.001] in favour of
the new P2Y12 receptor inhibitors (prasugrel and ticagrelor combined). In the comparison between prasugrel and
ticagrelor, there were no relevant differences (OR 0.97, 95% CI 0.77–1.23; P=0.81). Event rates of cardiovascular
death and stroke were also substantially lower for the new P2Y12 receptor inhibitors. The differences between clo-
pidogrel and prasugrel or ticagrelor on major bleeding were numerically in the same order as for death of any
cause but were not statistically significant. No differences in ischaemic and bleeding outcomes were observed be-
tween prasugrel and ticagrelor.
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Conclusion This analysis suggests that the prasugrel or ticagrelor compared with clopidogrel have favourable outcomes in clin-
ical practice while not being inferior in terms of safety.
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Contemporary European Society of Cardiology (ESC) guidelines
highlight the benefit of dual antiplatelet therapy (DAPT) consisting of
acetylic salicylic acid (ASA) plus one of the P2Y12 receptor inhibitors,
i.e. clopidogrel with a preference for prasugrel, or ticagrelor, with the
aim to reduce the risk of both acute ischaemic complications and re-
current atherothrombotic events.1,2 Based on their higher antithrom-
botic potency and proven superiority in outcome trials, prasugrel and
ticagrelor are given preference over clopidogrel.1,2 Recently, a direct
comparison of ticagrelor and prasugrel suggested superiority of the
latter compared with the former.3
Although prior studies have compared prasugrel or ticagrelor with
clopidogrel in a real-world setting, a head-to-head comparison be-
tween the three available antiplatelet agents have never been
performed.
We aimed to investigate whether in real-word practice, the newer
P2Y12 inhibitors prasugrel and ticagrelor are indeed superior to clopi-
dogrel. We used the ‘Platelet Inhibition Registry in ACS EvalUation
Study’ (PIRAEUS) platform which was initiated in 2014 to integrate
data generated by individual European registries on acute coronary
syndromes (ACS) to gain a comprehensive overview on the effect-
iveness and safety of the P2Y12 receptor inhibitors.
4 The participating
registries have been described in narrative and tabular form in detail
in an earlier review of this group,4 and the non-ST-elevation myocar-
dial infarction (NSTEMI)5 and ST-segment elevation myocardial in-
farction (STEMI) cohorts.6
This study presents data on STEMI patients from five European
registries, with a focus on effectiveness (all-cause deaths) and safety
(bleeding) for P2Y12 receptor inhibitor-based DAPT specifically. In
the assessment of effectiveness and safety endpoints, to account for
differences in patient composition, a matched pair strategy and pro-
pensity scoring was used.
Methods
The original PIRAEUS data set consists of 12 ACS registries and studies
which are heterogenous in terms of setting, duration, documented varia-
bles, and endpoints.4 The criteria to select suitable registries were as fol-
lows: European multicentre or single-centre observational studies on
real-life experience in the management of ACS within the last 5 years;
large unselected STEMI patient cohorts; data on percutaneous coronary
intervention (PCI); data on management during initial hospitalization for
ACS available; information on specific P2Y12 inhibitor treatment pre-cath
or in-cath lab; follow-up data on outcomes (death, cardiac events, and
bleedings) available; and willingness of registry owners to share data. Five
registries met the criteria: AMIS Plus, Belgium STEMI, ALKK-PCI, APCI/
ADAPT, and EYESHOT. A description of these registries that provided
STEMI data has been provided previously.6
All participating registries were national projects. Two were a running
registry with no specified stop date for inclusion of patients (AMIS Plus
and Belgium STEMI database), while the others included cohorts of
patients within a defined time frame.
Registry owners were asked to provide detailed current data on
STEMI patients treated with the P2Y12 receptor inhibitors prasugrel, tica-
grelor, or clopidogrel. While the registries collected individual patient
data prospectively, for the purpose of this analysis, aggregate data in tabu-
lar format were used. Endpoints of interest comprised in-hospital events,
such as all-cause death, cardiovascular (CV) death, stroke, recurrent
myocardial infarction (MI), and repeat percutaneous coronary interven-
tion (PCI) for effectiveness, and life-threatening/major and minor bleed-
ing. For bleeding events, the definition (e.g. BARC) was requested from
the registry owners but was not always available or sometimes changed
during the registry data collection. Registry owners were asked to pro-
vide percentages for the various events together with event number and
patient number at the various time points.
Statistical analysis
Patients who received either new P2Y12 receptor inhibitors (prasugrel
and ticagrelor combined) or clopidogrel during pre-cath or in-cath treat-
ment were included in the analysis. Patients administered more than one
kind of P2Y12 receptor inhibitors during pre-cath or in-cath treatment
were excluded from the event analysis.
Propensity score matching7 of new P2Y12 receptor inhibitors and clo-
pidogrel was based on one-to-one matching without replacement strati-
fied by registry. The propensity score was estimated using logistic
regression on a study-by-study basis including the following 24 baseline
covariates: age, gender, diabetes mellitus, heart failure, atrial fibrillation,
prior MI, previous stroke/transient ischaemic attack (TIA), previous cor-
onary artery bypass grafting (CABG), arterial hypertension, peripheral ar-
terial disease, hypercholesterolaemia, current smoking, chronic kidney
disease, Killip class >2, chronic ASA, chronic P2Y12 receptor inhibitors,
chronic oral anticoagulation, multivessel disease, >1 stent implanted, and
pre-cath or in-cath lab treatments [glycoprotein IIb/IIIa inhibitors (GPI),
unfractionated heparin, lowmolecular weight heparin (LMWH), and biva-
lirudin]. The estimated propensity score was the predicted probability of
treated new P2Y12 receptor inhibitor from the logistic regression model.
A greedy, nearest-neighbour matching algorithm was employed to match
patients on the logit of the propensity score using calipers of width equal
to 0.1 of the propensity score logit. The balance in baseline characteristics
between matched patients was assessed by standardized differences.8
Odds ratio (OR) and 95% confidence interval (CI) of new P2Y12 receptor
inhibitors group compared with clopidogrel group on in-hospital events
was estimated using the conditional logistic regression model stratified by
matched pairs (Analysis 1). In-hospital death, CV death, stroke/TIA, and
any major bleeding [intracranial haemorrhage (ICH), fatal bleeding, or
Thrombolysis in Myocardial Infarction (TIMI) major bleeding] were used
as the outcome variables in the event analysis. Propensity score-matched
analyses to compare between prasugrel and ticagrelor were done by
using similar models (Analysis 2).
Means and standard deviation were calculated for continuous varia-
bles, and percentages were calculated for categorical variables based on
the total number of patients excluding missing and unknown data.
Statistical significance level was considered as two-sided P-value of 5%. All
statistical analyses were performed using SAS version 9.4 (SAS Institute,
Cary, NC, USA) software.
Results
Patient disposition
We collected data on a total of 36 553 STEMI patients. The sample
size between registries varied considerably (from n=1066 in
EYESHOT to n=13 916 in AAPCI/ADAPT). Of these, a total of
25 250 patients met the inclusion criteria for in-hospital event analysis
(see Methods section) before matching patients. No patient in the
BELGIUM STEMI registry met the inclusion criteria, because antipla-
telet therapies during pre-cath or in-cath treatment were not















































































































recorded in the registry (only antiplatelet therapy at discharge). After
matching patients, a total of 15 120 patients (Analysis 1) and 8910
(Analysis 2) were included in the in-hospital event analysis (Figure 1).
Risk factors and comorbidities by registry are shown in Table 1. In
all registries, the proportion of males (range 72.0–76.0%) was higher
than of females. Mean age ranged between 62.5 and 66.0 years.
Comorbidities were frequent, in particular, arterial hypertension
(range 39.5–70.9%), hypercholesterolaemia (range 31.0–58.9%), and
diabetes mellitus (range 16.4–22.4%). Prior MI was reported in 10.1–
20.1% and current smoking in 38.5–47.9%.
ST-elevation MI characteristics and pre-treatment are shown in
Table 2. The STEMI location was slightly more often in the inferior ar-
tery (range 49.8–57.4%) compared with the anterior (41.6–44.3%).
Killip Class I prevailed (66.4–85.7%). Chronic pre-treatment was
Figure 1 Patient disposition.























































































































































reported for ASA in 20.0–28.7%, clopidogrel in 3.1–10.9%, prasugrel
in 0.6–4.4%, and P2Y12 overall in 3.8–15.4%. Chronic pre-treatment
with anticoagulation was noted in 3.8–11.6%.
Information on the timing and in-hospital management are given in
Supplementary material online, Table S1. The timing from first medic-
al contact to PCI was 79–101min. Coronary angiography was per-
formed in 94.0–100.0%.
Pre-cath and in-cath lab treatment are presented in
Supplementary material online, Table S2. The information on pre-
cath lab treatment was available for AAPCI/ADPAT, AMIS Plus, and
EYESHOT. In these registries, ASA was given in 77.0–96.6%, clopi-
dogrel in 28.8–46.7%, prasugrel in 18.0–21.9%, and ticagrelor in 16.7–
24.5%. In-cath lab treatment was available for AAPCI/ADAPT, ALKK,
and EYESHOT. Acetylic salicylic acid was routinely used in ALKK
(93.0%), and rarely in EYESHOT (13.0%) and AAPCI/ADAPT (0.1%).
Clopidogrel use ranged between 10.8% and 60.2%, prasugrel be-
tween 8.8% and 43.5%, and ticagrelor between 2.1% and 20.6%.
Table 3 displays discharge treatments, which were based on ASA
(96.9– 99.3%), and also included clopidogrel (10.7–48.1%), prasugrel
(24.4–31.3%), and ticagrelor (20.6–64.9%).
Data on in-hospital events are presented in Table 3 bottom. Data
on death were available in all registries and ranged from 3.5% to 7%,
data on CV death from AAPCI/ADAPT, AMIS Plus, and EYESHOT
ranging from 1.9% to 3.5%. Stroke/TIA was reported in 0.3–0.8%.
Information on bleeding, depending on the definition, was heteroge-
neous: fatal bleeding as reported in AMIS Plus and EYESHOT was
0.1% each, TIMI major bleeding in AAPCI/ADPAT and EYESHOT
was 0.9% and 1.3%. Urgent revascularization in AAPCI/ADPAT and
EYESHOTwas 0.8% and 1.1%, respectively.
Event analysis before matching patients
Baseline patient characteristics in all registries before matching
patients were widely different between new P2Y12 receptor inhibitor
(prasugrel and ticagrelor combined) and clopidogrel. After matching
patients, these imbalances were largely improved and the standar-
dized differences in most of the patient characteristics in each registry
were within 10% (Supplementary material online, Tables S1-1–S1-4
and S2-1–S2-4). It was not possible to match patients in ALKK-PCI
for Analysis 2 due to small number of patients who received
ticagrelor.
....................................................................................................................................................................................................................
Table 1 Baseline characteristics: risk factors and comorbidities
Registry acronym AAPCI/ADAPT ALKK AMIS Plus BELGIUM EYESHOT
Patient number, n 13 916 3553 10 224 7794 1066
Year of enrollment, n (%) 13 916 3553 10 224 7794 1066
Before 2009 1640 (11.8) 104 (2.9) 0 (0.0) 0 (0.0) 0 (0.0)
2010 1359 (9.8) 1061 (29.9) 0 (0.0) 0 (0.0) 0 (0.0)
2011 1889 (13.6) 1284 (36.1) 1461 (14.3) 0 (0.0) 0 (0.0)
2012 1822 (13.1) 1104 (31.1) 1786 (17.5) 0 (0.0) 0 (0.0)
2013 1770 (12.7) 0 (0.0) 1966 (19.2) 0 (0.0) 844 (79.2)
2014 1392 (10.0) 0 (0.0) 1837 (18.0) 1133 (14.5) 222 (20.8)
2015 1393 (10.0) 0 (0.0) 1499 (14.7) 2685 (34.4) 0 (0.0)
2016 1137 (8.2) 0 (0.0) 1202 (11.8) 2482 (31.8) 0 (0.0)
After 2017 1514 (10.9) 0 (0.0) 473 (4.6) 1494 (19.2) 0 (0.0)
Age (years), mean (SD) 62.5 (13.1) 62.7 (13.0) 64.2 (12.8) 63.3 (13.1) 66.0 (13.1)
Age >75 years, n (%) 2860/13 916 (20.6) 754/3553 (21.2) 2352/10 224 (23.0) 1718/7794 (22.0) 308/1066 (28.9)
Risk factors and comorbidities, n (%)
Males 10 177/13 916 (73.1) 2641/3553 (74.3) 7770/10 224 (76.0) 5891/7766 (75.9) 767/1066 (72.0)
Diabetes mellitus 2065/11 875 (17.4) 746/3330 (22.4) 1659/9799 (16.9) 1269/7717 (16.4) 223/1041 (21.4)
Heart failure 284/2108 (13.5) 387/3521 (11.0) 147/8880 (1.7) NA 13/1064 (1.2)
Atrial fibrillation 971/10 949 (8.9) 77/1048 (7.3) 343/9077 (3.8) NA NA
Prior myocardial infarction 1294/12 766 (10.1) 688/3422 (20.1) 1220/9998 (12.2) 1200/7714 (15.6) 121/1058 (11.4)
Previous stroke/TIA 394/12 155 (3.2) 140/3290 (4.3) 386/10 027 (3.8) NA 56/1056 (5.3)
Previous PCI 1642/12 956 (12.7) 533/3457 (15.4) 1328/10 000 (13.3) NA 107/1063 (10.1)
Previous CABG NA 125/3508 (3.6) 281/10 000 (2.8) NA 24/1064 (2.3)
Arterial hypertension 1395/3528 (39.5) 2232/3150 (70.9) 5407/9750 (55.5) 3673/7719 (47.6) 620/1029 (60.3)
Peripheral arterial disease 122/3528 (3.5) 159/3252 (4.9) 380/10 027 (3.8) 552/7710 (7.2) 93/1019 (9.1)
Hypercholesterolaemia 1093/3528 (31.0) 1283/2768 (46.4) 5453/9261 (58.9) 3813/7160 (53.3) 381/921 (41.4)
Current smoking 5461/12 467 (43.8) 1457/3040 (47.9) 4124/9171 (45.0) 2974/7169 (41.5) 405/1053 (38.5)
Chronic kidney disease 2050/11 834 (17.3) 373/3285 (11.4) 455/10 028 (4.5) 607/7158 (8.5) 90/1036 (8.7)
Percentages are based on the total number of patients excluding missing and unknown data. For BELGIUM, prior MI includes prior PCI and CABG. CKD is defined as either
serum creatinine >1.5mg/dL or eGFR <60/mL/m2. For AAPCI-ADAPT, prior PCI includes prior CABG. CABG, coronary artery bypass grafting; NA, not applicable; TIA, transi-
ent ischaemic attack.










































































































































Before matching patients, the overall cumulative event rates of
new P2Y12 receptor inhibitor, prasugrel, ticagrelor, and clopidogrel
on in-hospital events were 3.2%, 2.6%, 3.9%, and 6.3% on death,
1.5%, 1.3%, 1.7%, and 4.5% on CV death, 0.4%, 0.3%, 0.6%, and 0.8%
on stroke/TIA, and 0.4%, 0.4%, 0.4%, and 0.8% on any major bleed-
ings, respectively.
Event analysis after matching procedure
Figure 2presents in-hospital events, by single events, differentiated by
new P2Y12 receptor inhibitor vs. clopidogrel as administered as pre-
cath or in-cath lab treatment with matched population. As a consist-
ent finding, the event rates appeared substantially lower with the new
P2Y12 receptor inhibitors (with an exception for any major bleeding
with low event rates). The ORs of the new P2Y12 receptor inhibitors
for the death of any cause, CV death, stroke/TIA, and any major
bleeding when compared with clopidogrel were 0.72 (95% CI 0.62–
0.84, P<0.001), 0.70 (95% CI 0.52–0.96, P=0.026), 0.52 (95% CI
0.33–0.80, P=0.003), and 0.81 (95% CI 0.53–1.24, P=0.335),
respectively.
The standardized differences for all covariates in the matched
patients were <10% after integrating registries (Supplementary ma-
terial online, Tables S1-5 and S2-5).
Upon further differentiation, event rates of prasugrel and ticagre-
lor appeared similar across registries (Analysis 2; Figure 3). In the
comparison between prasugrel and ticagrelor, there were no signifi-
cant differences on any event.
Discussion
The present analysis of contemporary European real-world registries
suggests that in STEMI patients the newer P2Y12 receptor inhibitors
....................................................................................................................................................................................................................
Table 2 Information on STEMI at admission and pre-treatment
Registry acronym AAPCI/ADAPT ALKK AMIS Plus BELGIUM EYESHOT
Patient number, n 13 916 3553 10 224 7794 1066
Admission
Rhythm at ECG, n (%) 12 318 9077 . 1053
Sinus rhythm 11 098 (90.1) NA 8310 (91.6) NA 980 (93.1)
Atrial fibrillation 945 (7.7) NA 343 (3.8) NA 56 (5.3)
Others 275 (2.2) NA 424 (4.7) NA 17 (1.6)
STEMI location, n (%) 13 914 . 10 178 7747 1066
Inferior 6935 (49.8) NA 5291 (52.0) 4449 (57.4) 584 (54.8)
Anterior 6166 (44.3) NA 4288 (42.1) 3224 (41.6) 467 (43.8)
Undetermined 813 (5.8) NA 599 (5.9) 74 (1.0) 15 (1.4)
Killip class, n (%) 10 801 . 10 164 7681 1031
I 7176 (66.4) NA 8706 (85.7) 6246 (81.3) 811 (78.7)
II 2123 (19.7) NA 722 (7.1) 662 (8.6) 151 (14.6)
III 616 (5.7) NA 238 (2.3) 214 (2.8) 31 (3.0)
IV 886 (8.2) NA 498 (4.9) 559 (7.3) 38 (3.7)
Killip class >2, n (%) 1502/10 801 (13.9) NA 736/10 164 (7.2) 773/7681 (10.1) 69/1031 (6.7)
Pre-treatment, n (%)
Chronic ASA 579/2893 (20.0) 520/2276 (22.8) 2466/8595 (28.7) NA 243/1048 (23.2)
Chronic clopidogrel 88/2864 (3.1) 389/3553 (10.9) 359/8462 (4.2) NA 35/1055 (3.3)
Chronic prasugrel 17/2899 (0.6) 156/3553 (4.4) 77/8423 (0.9) NA 4/1056 (0.4)
Chronic ticagrelor 10/2815 (0.4) 1/1069 (0.1) 64/6972 (0.9) NA 8/1057 (0.8)
Chronic P2Y12 receptor inhibitor 115/3026 (3.8) 546/3553 (15.4) 499/8489 (5.9) NA 47/1057 (4.4)
Chronic oral anticoagulation 110/2862 (3.8) 46/1104 (4.2) 1015/8719 (11.6) NA 33/1057 (3.1)
Vital sign
SBP
n 10 626 9864 4090 1066
Mean (SD) 133.0 (29.2) NA 131.8 (27.6) 131.0 (30.7) 130.6 (25.2)
DBP
n 10 386 9851 4110 1066
Mean (SD) 78.4 (16.5) NA 78.3 (17.0) 78.1 (20.7) 76.5 (14.8)
HR
n 10 584 9825 1066
Mean (SD) 78.5 (19.3) NA 78.5 (18.4) NA 79.1 (19.0)
Percentages are based on the total number of patients excluding missing and unknown data. For vital signs, extreme data with <10 or >300 were excluded. For STEMI location,
lateral, inferolateral, and posterior are merged into ‘inferior’. Antero-lateral is merged into ‘anterior’.




















































































































































compared with clopidogrel have more favourable in-hospital out-
comes, while not being inferior in terms of safety.
With respect to the setting, the majority of registries, including
ALKK and APCI focused on selected (tertiary) hospitals, while others
were open to all types of hospitals (AMIS Plus). Thus, the consider-
able differences in outcomes between the registries are likely
explained by their designs. Overall across all analysed registries, how-
ever, in-hospital mortality rates associated with STEMI were quite
low and homogeneous. Reasons that might account for this finding in-
clude selection bias (fewer ill patients might have been preferentially
recruited) and improved ACS management over the years.9 Patients
in the five registries were similar in age and gender distribution.
However, they differed substantially in the prevalence of comorbid-
ities, such as arterial hypertension, diabetes mellitus, or prior MI.
Death rates, ischaemic events, and bleeding rates were overall
lower than those reported in Phase III studies with P2Y12 inhibitors.
Regarding individual P2Y12 inhibitors, patients on prasugrel, and, to a
lesser degree, ticagrelor, had fewer ischaemic and bleeding events at
all time points than clopidogrel-treated patients. These findings are
partly related to the fact that the newer agents were used in younger
and less ill patients.
A thorough comparison of various P2Y12 inhibitors can be only
be made in the presence of appropriate adjustment techniques
reducing indication biases that registries are prone to. In line with
its labelling, the registries consistently documented that prasugrel
in everyday practice conditions is used in younger patients, com-
pared with other antiplatelet agents as recommended by the ESC
Guidelines.1,2 This age difference reflects the somewhat restricted
labelling, as prasugrel is contraindicated in patients with prior TIA
or stroke, and the drug is generally not recommended in elderly
patients (>_75 years), although maintenance dose adaptation (5mg
instead of 10mg) may be considered in such patients.10 According
to the product labelling, ticagrelor should be used with caution in
patients with a history of asthma and/or chronic obstructive pul-
monary disease (due to a relatively high incidence of dyspnoea)
and also in patients with renal impairment (due to creatinine level
increases).11 These side effects have not been systematically
assessed in the registries contributing to PIRAEUS.
....................................................................................................................................................................................................................
Table 3 Discharge treatment and events in-hospital and within 30 days after discharge in propensity-matched
populations
Registry acronym AAPCI/ADAPT ALKK AMIS Plus BELGIUM EYESHOT
Patient number, n 13 916 3553 10 224 7794 1066
Discharge treatment, n (%)
ASA 13 347/13 437 (99.3) NA 9629/9801 (98.2) NA 993/1025 (96.9)
Clopidogrel 6102/12 680 (48.1) NA 2424/9770 (24.8) 654/6114 (10.7) 350/1025 (34.1)
Prasugrel 3969/12 679 (31.3) NA 4268/9767 (43.7) 1489/6114 (24.4) 267/1025 (26.0)
Ticagrelor 2608/12 665 (20.6) NA 2797/8691 (32.2) 3971/6114 (64.9) 353/1025 (34.4)
Oral anticoagulation 214/2714 (7.9) NA 650/9720 (6.7) NA 48/1025 (4.7)
In-hospital events, n (%)
Death 805/13 916 (5.8) 124/3553 (3.5) 416/10 224 (4.1) 531/7613 (7.0) 41/1066 (3.8)
Cardiovascular death 111/3528 (3.1) NA 195/10 204 (1.9) NA 37/1066 (3.5)
Stroke/TIA 74/13 848 (0.5) 11/3553 (0.3) 70/10 224 (0.7) NA 9/1066 (0.8)
ICH 31/13 916 (0.2) NA 2/358 (0.6) NA 0/1066 (0.0)
Fatal bleeding NA NA 10/9850 (0.1) NA 1/1066 (0.1)
TIMI major bleeding 131/13 916 (0.9) NA NA NA 14/1066 (1.3)
Any major bleeding 131/13 916 (0.9) NA 12/9850 (0.1) NA 14/1066 (1.3)
TIMI minor bleeding 40/3528 (1.1) NA NA NA 24/1066 (2.3)
Urgent revascularization 28/3463 (0.8) NA NA NA 12/1066 (1.1)
Events within 30 days after discharge, n (%)
Death NA NA NA 196/3264 (6.0) NA
Cardiovascular death NA NA NA NA NA
Stroke/TIA NA NA NA NA NA
ICH NA NA NA NA NA
Fatal bleeding NA NA NA NA NA
TIMI major bleeding NA NA NA NA NA
Any major bleeding NA NA NA NA NA
TIMI minor bleeding NA NA NA NA NA
Urgent revascularization NA NA NA NA NA
ICH: intracranial haemorrhage.
Percentages are based on the total number of patients excluding missing and unknown data. Other events within 30 days after discharge except for death are not available in all
registries. Any major bleeding includes ICH, fatal bleeding, and TIMI major bleeding.


















































































































Trials comparing clopidogrel with either prasugrel or ticagrelor
found a superior effectiveness of the novel antiplatelet agents,12,13
even in STEMI patients.14,15
Prior studies have compared prasugrel or ticagrelor with clopidog-
rel also in a real-world setting, but a head-to-head comparison be-
tween the three available antiplatelet agents has never been
performed. An AMIS Plus analysis using a propensity score-matched
pairs analysis found significantly lower in-hospital mortality with
prasugrel (1.8%) vs. clopidogrel (3.1%).16 In MULTIPRAC, a multi-
national, multicentre, prospective registry enrolling 2053 STEMI
patients, after adjustment for differences in baseline characteristics
(including a 10-year age difference), treatment with prasugrel was
associated with a significantly lower risk of CV death than treatment
with clopidogrel (OR 0.248, 95% CI 0.06–0.89; data submitted).17 In
the SCAAR registry, the age difference was 2 years only, but the dif-





Figure 2 Relationship between the type of P2Y12 treatment and events in-hospital in propensity-matched populations (Analysis 1).





































































































































vs. clopidogrel 5.0%).18 Accordingly, a prospective cohort study of
45 073 ACS patients enrolled into the SWEDEHEART registry con-
firmed the results of the PLATO trial as ticagrelor was associated
with a lower risk of death, MI, or stroke compared with clopidogrel
[11.7 vs. 22.3%; adjusted hazard ratio (HR) 0.85, 95% CI: 0.78–0.93],
as well as death alone (5.8 vs. 12.9%; adjusted HR 0.83 95% CI: 0.75–
0.92).19 Re-admission for bleeding occurred more frequently with
ticagrelor vs. clopidogrel (5.5 vs. 5.2%; adjusted HR 1.20, 95% CI
1.04–1.40).19
Recently, ticagrelor and prasugrel have been directly compared in
the multicentre, randomized, open-label ISAR-REACT 5 trial.3
Among the 4018 patients with ACS enrolled in this trial, a primary
endpoint event—death from any cause, MI, or stroke at 1 year after
randomization—occurred in 9.1% of patients in the ticagrelor group
and 6.8% in the prasugrel group (HR 1.36, 95% CI: 1.09–1.70;
P=0.006), without any difference in terms of major bleeding events
(BARC Type 3 through 5). Among the pre-specified subgroup of
patients with STEMI no difference was observed in terms of primary
efficacy (10.1 vs. 7.9; HR 1.31, 95% CI 0.94–1.81) and safety endpoint
across all enrolled patients, including those with STEMI.3 These find-
ings are in accordance with our real-world data showing a numerical,
not significant reduction in the ischaemic event rate associated with
prasugrel compared with ticagrelor, with a similar occurrence of
bleeding events during the hospitalization for STEMI.
Limitations
Not all of the previously identified suitable registries6 provided data





Figure 3 Relationship between the type of P2Y12 treatment and events in-hospital in propensity-matched populations (Analysis 2).







































































































































































































































































therefore, not be analysed for the purpose of this article.
Outcomes analyses were restricted to the short in-hospital
period and does not allow for long-term assessment. The con-
current use of oral anticoagulation and other anticoagulants, such
as unfractionated heparin, low-molecular-weight heparins, and
fondaparinux, needs to be taken into account. Bleeding events
were categorized using various definitions and were not standar-
dized across registries. The low rate of bleeding complications is
noteworthy, as real-life data are usually more likely to document
increased safety hazards, compared with randomized controlled
trials.
In conclusion, the present analysis of contemporary European
registries suggests that in clinical practice STEMI patients the
newer P2Y12 receptor inhibitors compared with clopidogrel have
favourable in-hospital outcomes while not being inferior in terms
of safety.
Supplementary material
Supplementary material is available at European Heart Journal –
Cardiovascular Pharmacotherapy online.
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Lemesle G, Lüscher TF, Matter CM, Montalescot G, Radovanovic D, Sendón JL,
Tousek P, Weidinger F, Weston CF, Zaman A, Andell P, Li J, Jukema JW. P2Y12
receptor inhibitors in patients with non-ST-elevation acute coronary syndrome
in the real world: use, patient selection, and outcomes from contemporary
European registries. Eur Heart J Cardiovasc Pharmacother 2016;2:229–243.
6. Danchin NL, Maddalena Zeymer U, Widimsky P, Danchin N, Bardaji A, Barrabes
JA, Cequier A, Claeys MJ, De Luca L, Dörler J, Erlinge D, Erne P, Goldstein P,
Koul SM, Lemesle G, Lüscher TF, Matter CM, Montalescot G, Radovanovic D,
Lopez Sendón J, Tousek P, Weidinger F, Weston CF, Zaman A, Andell P, Li J,
Jukema JW. Use, patient selection and outcomes of P2Y12 receptor inhibitor
treatment in patients with STEMI based on contemporary European registries.
Eur Heart J Cardiovasc Pharmacother 2016;2:152–167.
7. Rosenbaum P, Rubin D. The central role of the propensity score in observational
studies for causal effects. Biometrika 1983;70:41–55.
8. Austin PC. Some methods of propensity-score matching had superior perform-
ance to others: results of an empirical investigation and Monte Carlo simulations.
Biom J 2009;51:171–184.
9. Bjorklund E, Nielsen SJ, Hansson EC, Karlsson M, Wallinder A, Martinsson A,
Tygesen H, Romlin BS, Malm CJ, Pivodic A, Jeppsson A. Secondary prevention
medications after coronary artery bypass grafting and long-term survival: a
population-based longitudinal study from the SWEDEHEART registry. Eur Heart
J 2019; pii: ehz714. doi: 10.1093/eurheartj/ehz714. [Epub ahead of print].
10. Efient(R) Summary of Product Characteristics. http://www.ema.europa.eu (20
January 2020).
11. European Medicines Agency (EMA). Brillque(R). Ticagrelor Summary of Product
Characteristics and Package Leaflet. http://www.emea.europa.eu. (20 January
2020).
12. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S,
Neumann F-J, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G,
Gibson CM, Antman EM, TRITON-TIMI 38 Investigators. Prasugrel versus





































































































































clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:
2001–2015.
13. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J,
Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey
RF, Harrington RA, Investigators P, Freij A, Thorsén M. Ticagrelor versus clopidog-
rel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057.
14. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH,
Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidog-
rel in patients undergoing percutaneous coronary intervention for ST-elevation
myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled
trial. Lancet 2009;373:723–731.
15. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP,
Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey
RF, Weaver WD, Wallentin L; PLATO Study Group. Ticagrelor versus clopidogrel
in patients with ST-elevation acute coronary syndromes intended for reperfusion
with primary percutaneous coronary intervention: a Platelet Inhibition and Patient
Outcomes (PLATO) trial subgroup analysis. Circulation 2010;122:2131–2141.
16. Kurz DJ, Radovanovic D, Seifert B, Bernheim AM, Roffi M, Pedrazzini G,
Windecker S, Erne P, Eberli FR. Comparison of prasugrel and clopidogrel-
treated patients with acute coronary syndrome undergoing percutaneous coron-
ary intervention: a propensity score-matched analysis of the Acute Myocardial
Infarction in Switzerland (AMIS)-Plus Registry. Eur Heart J Acute Cardiovasc Care
2016;5:13–22.
17. Clemmensen P, Grieco N, Ince H, Danchin N, Goedicke J, Ramos Y, Schmitt J,
Goldstein P. MULTIPRAC study investigators. MULTInational non-interventional
study of patients with ST-segment elevation myocardial infarction treated with
PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with
prasugrel or clopidogrel–the European MULTIPRAC Registry. Eur Heart J Acute
Cardiovasc Care 2015;4:220–229.
18. Damman P, Varenhorst C, Koul S, Eriksson P, Erlinge D, Lagerqvist B, James SK.
Treatment patterns and outcomes in patients undergoing percutaneous coron-
ary intervention treated with prasugrel or clopidogrel (from the Swedish
Coronary Angiography and Angioplasty Registry [SCAAR]). Am J Cardiol 2014;
113:64–69.
19. Sahlen A, Varenhorst C, Lagerqvist B, Renlund H, Omerovic E, Erlinge D,
Wallentin L, James SK, Jernberg T. Outcomes in patints treated with ticagrelor
or clopidogrel after acute myocardial infarction: experiences from
SWEDEHEART registry. Eur Heart J 2016;37:3335–3342.
10 L. De Luca et al.
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/e
h
jc
v
p
/a
d
v
a
n
c
e
-a
rtic
le
/d
o
i/1
0
.1
0
9
3
/e
h
jc
v
p
/p
v
a
a
0
0
2
/5
7
1
3
5
1
7
 b
y
 g
u
e
s
t o
n
 2
7
 J
a
n
u
a
ry
 2
0
2
1
